A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease

F. C. Crawford, M. J. Freeman, J. A. Schinka, L. I. Abdullah, M. Gold, R. Hartman, K. Krivian, M. D. Morris, D. Richards, R. Duara, R. Anand, M. J. Mullan

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a signficant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE ε4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age. Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author's dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.

Original languageEnglish
Pages (from-to)763-768
Number of pages6
JournalNeurology
Volume55
Issue number6
StatePublished - Sep 26 2000
Externally publishedYes

Fingerprint

Cystatin C
Alzheimer Disease
Genes
Genotype
Age of Onset
Cysteine Proteinase Inhibitors
Genetic Association Studies
Age Groups
Population

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Crawford, F. C., Freeman, M. J., Schinka, J. A., Abdullah, L. I., Gold, M., Hartman, R., ... Mullan, M. J. (2000). A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology, 55(6), 763-768.

A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. / Crawford, F. C.; Freeman, M. J.; Schinka, J. A.; Abdullah, L. I.; Gold, M.; Hartman, R.; Krivian, K.; Morris, M. D.; Richards, D.; Duara, R.; Anand, R.; Mullan, M. J.

In: Neurology, Vol. 55, No. 6, 26.09.2000, p. 763-768.

Research output: Contribution to journalArticle

Crawford, FC, Freeman, MJ, Schinka, JA, Abdullah, LI, Gold, M, Hartman, R, Krivian, K, Morris, MD, Richards, D, Duara, R, Anand, R & Mullan, MJ 2000, 'A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease', Neurology, vol. 55, no. 6, pp. 763-768.
Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology. 2000 Sep 26;55(6):763-768.
Crawford, F. C. ; Freeman, M. J. ; Schinka, J. A. ; Abdullah, L. I. ; Gold, M. ; Hartman, R. ; Krivian, K. ; Morris, M. D. ; Richards, D. ; Duara, R. ; Anand, R. ; Mullan, M. J. / A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. In: Neurology. 2000 ; Vol. 55, No. 6. pp. 763-768.
@article{b64b1203db59475faeeb2d9addf32d7c,
title = "A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease",
abstract = "Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a signficant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE ε4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age. Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author's dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.",
author = "Crawford, {F. C.} and Freeman, {M. J.} and Schinka, {J. A.} and Abdullah, {L. I.} and M. Gold and R. Hartman and K. Krivian and Morris, {M. D.} and D. Richards and R. Duara and R. Anand and Mullan, {M. J.}",
year = "2000",
month = "9",
day = "26",
language = "English",
volume = "55",
pages = "763--768",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease

AU - Crawford, F. C.

AU - Freeman, M. J.

AU - Schinka, J. A.

AU - Abdullah, L. I.

AU - Gold, M.

AU - Hartman, R.

AU - Krivian, K.

AU - Morris, M. D.

AU - Richards, D.

AU - Duara, R.

AU - Anand, R.

AU - Mullan, M. J.

PY - 2000/9/26

Y1 - 2000/9/26

N2 - Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a signficant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE ε4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age. Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author's dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.

AB - Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a signficant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE ε4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age. Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author's dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.

UR - http://www.scopus.com/inward/record.url?scp=0034718576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034718576&partnerID=8YFLogxK

M3 - Article

C2 - 10993992

AN - SCOPUS:0034718576

VL - 55

SP - 763

EP - 768

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -